10 mm Hg in mean pulmonary artery pressure [mPAP] to <40 mm Hg) confers an excellent prognosis in patients with idiopathic pulm'/> Prognostic value of acute vasodilator response in pulmonary arterial hypertension: Beyond the 'classic' responders
首页> 外文期刊>The Journal of heart and lung transplantation: the official publication of the International Society for Heart Transplantation >Prognostic value of acute vasodilator response in pulmonary arterial hypertension: Beyond the 'classic' responders
【24h】

Prognostic value of acute vasodilator response in pulmonary arterial hypertension: Beyond the 'classic' responders

机译:急性血管扩张反应在肺动脉高压中的预后价值:超越“经典”反应者

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: A "classic" response to acute vasodilator testing (drop of >10 mm Hg in mean pulmonary artery pressure [mPAP] to <40 mm Hg) confers an excellent prognosis in patients with idiopathic pulmonary arterial hypertension (IPAH) and identifies candidates for treatment with calcium channel blockers (CCB). Little is known about vasodilator responsiveness (VR) in other types of PAR, or about outcomes in patients with a significant but "non-classic" decrease in mPAP. We hypothesized that VR occurs in non-idiopathic PAH and non-classic VR portends a better prognosis than no VR in PAH.
机译:背景:对急性血管扩张剂测试的“经典”反应(平均肺动脉压[mPAP]下降> 10 mm Hg至<40 mm Hg)可为特发性肺动脉高压(IPAH)患者提供良好的预后,并确定其候选药物钙通道阻滞剂(CCB)进行治疗。对于其他类型的PAR中的血管扩张药反应性(VR)或mPAP显着但“非经典”下降的患者的预后知之甚少。我们假设VR发生在非特发性PAH中,非经典VR的预后要好于PAH中没有VR。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号